Skip to main content
Vista Pharmaceuticals Ltd. logo

Vista Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · 524711 ISIN · INE427C01021 LEI · 9845008A5F486P586T43 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country IN India
Listing BSE.NS 524711

About Vista Pharmaceuticals Ltd.

http://www.vistapharmaceuticals.com/

Vista Pharmaceuticals Ltd. specializes in the formulation, development, and manufacturing of a diverse range of medicinal products. The company focuses on producing dosage forms, including tablets, capsules, and liquids, across various therapeutic categories such as pain management, anti-infectives, gastrointestinal disorders, and respiratory ailments. Its operations emphasize compliance with international quality standards, catering to both domestic and global markets. The company’s core competencies lie in its research and development capabilities and its commitment to providing healthcare solutions through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
SEBI Secretarial Compliance Report for the year ended 31.03.2026
Regulatory Filings Classification · 85% confidence The document is a statutory Secretarial Compliance Report prepared by an external Practicing Company Secretary under SEBI LODR Regulation 24A, submitted to the stock exchange. It is not a full financial report (10-K, IR), nor an audit report of financial statements; rather it is a compliance certificate/filing. It does not announce an attached report but is the report itself of compliance. There is no category specifically for secretarial compliance, so it falls under the fallback Regulatory Filings (RNS).
2026-05-29 English
Board meeting outcome
Interim / Quarterly Report Classification · 90% confidence The document is a formal SEBI LODR filing of audited financial results at a board meeting, containing a full set of audited standalone financial statements for the quarter and year ended March 31, 2026, along with auditors’ report and notes. It is not a full annual report (10-K) with MD&A or a brief earnings press release (ER), nor is it merely an announcement (RPA). It is a statutory periodic financial report with detailed P&L, balance sheet, cash flows and notes, matching the Interim/Quarterly Report category (IR). FY 2026
2026-05-29 English
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. Audited financial ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about an upcoming Board Meeting scheduled to consider audited financial results and the audit report for the quarter and year ended 31.03.2026. It is an intimation of a board meeting under SEBI regulations, specifically Regulation 29(1)(a), which pertains to disclosure of board meetings. The document does not contain the financial results or audit report itself, but only announces the meeting where these will be considered. The document length is only 1293 characters, indicating it is a brief announcement rather than a full report. Therefore, this is a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Annual Report or Audit Report.
2026-05-19 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.